Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...

Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...

Researchers conducted a retrospective analysis of 1435 patients with limited cutaneous SSc from the Italian SPRING registry to assess the purpose of starting mycophenolate mofetil treatment and its ...

Please provide your email address to receive an email when new articles are posted on . Rheumatologists are likely to be at the “forefront” of diagnosing scleroderma skin disorders and other ...

Alicia M. Hinze, MD: In regard to treatment options, I’ll speak from the rheumatic side of treating interstitial lung disease, using scleroderma as probably 1 of the prototypical rheumatic diseases in ...

CellCept (mycophenolate mofetil) is a prescription drug used to prevent organ rejection following certain organ transplants. The drug comes in oral forms and as a liquid solution for injection. It’s ...

At The University of Texas Health Science Center at Houston (UTHealth), rheumatologist Shervin Assassi, M.D., is developing a blood test to determine which drugs work best for scleroderma patients ...

CellCept (mycophenolate mofetil) is a prescription drug that’s used to help prevent organ rejection after an organ transplant. The most common side effects reported with CellCept include diarrhea and ...